Acylated glucagon analogues

US9896495B2 · kind B2 · utility

Assignee

• Zealand Pharma A/S · DK

Inventors

• Ditte Riber · Copenhagen, DK
• Jakob Lind Tolborg · Avenue Madeleine, DK
• Dieter Hamprecht · Verona, IT
• Wolfgang Rist · Ingelheim am Rhein, DE

Key dates

• Filing date: Oct 17, 2014
• Grant date: Feb 20, 2018
• Expiry date: Oct 17, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.